Advicenne
2, rue Briçonnet
Nîmes
F-30 000
France
Tel: 33-466-05-54-20
Fax: 33-466-21-23-35
Website: http://advicenne.com
About Advicenne
Advicenne is a late-stage biopharmaceutical company focusing on the development of paediatric friendly therapeutics for the treatment of orphan renal and neurological diseases. The Company has a strong portfolio of products in late-stage development targeting critical unmet needs in nephrology and neurology. Advicenne also develops a clinical and pre-clinical pipeline of potential treatments for additional orphan diseases in collaboration with Key Opinion Leaders.YEAR FOUNDED:
2007
LEADERSHIP:
Founder and CEO: Luc-André Granier
CBO: Ludovic Robin
CLINICAL TRIAL:
Please click here for clinical trial information.
26 articles about Advicenne
-
Advicenne announces commercialization agreement with FrostPharma AB for Sibnayal™ in the Nordic region
1/4/2022
Advicenne is pleased to announce that it has signed an exclusive distribution agreement with FrostPharma AB, a Swedish pharmaceutical company, for the commercialization of Sibnayal™ in the Nordic region.
-
Advicenne announces positive opinion from the French Transparency Commission (HAS) for its drug SibnayalTM in dRTA
12/20/2021
Advicenne (Euronext: ADVIC), announces is has received a positive opinion from the French Transparency Commission (HAS) with its lead asset, SibnayalTM eligible for reimbursement with a Moderate Level SMR (Medical Rendered Service) and a Level IV ASMR (Medical Rendered Service Improvement).
-
Advicenne announces significant progress in marketing its lead product Sibnayal™ in Europe
12/7/2021
Advicenne announces significant progress in marketing its lead product Sibnayal™ in Europe,
-
Advicenne provides an update on its activities following its Annual General Meeting
6/15/2021
Advicenne, a specialty pharmaceutical company dedicated to developing and commercializing innovative treatments for those suffering from rare renal diseases, provides an update on its activities following its Annual General Meeting, which was held virtually on June 14, 2021.
-
Advicenne receives positive feedback from the US FDA on pathway to approval and amended Phase III study protocol for its treatment of distal renal tubular acidosis (dRTA)
5/17/2021
Advicenne (Euronext: ADVIC), a specialty pharmaceutical company dedicated to developing and commercializing innovative treatments for those suffering from rare renal diseases, announces US Food and Drug Administration (FDA) acceptance of the amended protocol of the Company’s US-based Phase III pivotal trial of ADV7103 (Sibnayal™) for the treatment of primary distal renal tubular acidosis (dRTA).
-
BioSpace Movers & Shakers, March 20
3/20/2020
Companies strengthen their leadership teams and board with this week's Movers & Shakers. -
BioSpace Global Roundup, June 13
6/13/2019
Companies from across the globe share business and pipeline updates. -
BioSpace Global Roundup, May 30
5/30/2019
Biopharma companies from across Europe, Asia and North America share updates on business decisions and pipeline development. -
Advicenne Reports Full Year 2018 Financial Results and Confirms Operational Outlook for 2019
3/21/2019
Advicenne, a pharmaceutical company specializing in the development of adult and pediatric therapeutic products for the treatment of orphan renal and neurological diseases, announces its financial results for the full year ended December 31, 2018.
-
Advicenne Announces Submission of European Marketing Authorization Application (MAA) for ADV7103 as Treatment for Distal Renal Tubular Acidosis (dRTA)
3/12/2019
Advicenne, specializing in the development of adult and pediatric therapeutic products for the treatment of orphan renal and neurological diseases, announces that it has submitted a Marketing Authorization Application to the European Medicines Agency for its lead drug candidate, ADV7103, as a treatment for distal renal tubular acidosis.
-
Advicenne Wins Prestigious Prix Galien - Medstartup Award for Best Innovative Trial Design Leading to Quicker and Better Therapeutic Outcomes
10/26/2018
Award recognizes ADV7103 in development for the treatment of distal Renal Tubular Acidosis (dRTA)
-
Advicenne Receives Health Canada Clearance to Extend its Pivotal Phase III Trial of ADV7103 in Canada
10/15/2018
Advicenne (Paris:ADVIC), a specialty pharmaceutical company focused on the development of pediatric-friendly therapeutics for the treatment of orphan renal and neurological diseases, announced today that it has received a No Objection Letter to extend its ARENA-2 pivotal Phase III trial
-
Advicenne to Present Additional Data on ADV7103 at the European Society for Paediatric Nephrology During Its 51st Annual Meeting
10/4/2018
Advicenne (Paris:ADVIC), a specialist pharmaceutical company focused on the development of pediatric-friendly therapeutics for the treatment of orphan renal and neurological diseases, announces today that the company strengthens its scientific relationship with the European Society for Paediatric Nephrology (ESPN) during the 51st Annual Meeting which is being held October 3-8, 2018, in Antalya, Turkey.
-
Advicenne Prepares its Expansion with Highly Experienced Industry Professionals
9/25/2018
Charlotte Sibley joins the Board of Directors as Independent Member
-
Advicenne to Host a Conference Call on September 12, 2018 at 6 PM to Comment on the Latest Positive Developments of Its Product Portfolio
9/11/2018
Advicenne today announced that the management of Advicenne will host a conference call on Wednesday September 12, 2018 at 6:00 pm (CEST) to comment on the latest positive developments of its product portfolio.
-
CORRECTING and REPLACING: Advicenne to Host a Conference Call on September 12, 2018 at 6 PM to Comment Its Recent Developments
9/11/2018
This replaces the announcement made at 06:45 pm CEST on 09/11/2018 due to the following corrections: correction in the title.
-
Advicenne Announces FDA Clearance of IND to Commence Pivotal Phase 3 Trial of ADV7103 for Distal Renal Tubular Acidosis
9/5/2018
Advicenne announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for ADV7103.
-
Advicenne Confirms ADV7103’ Safety and Efficacy after 24 Months in the Phase III Extension Study
7/2/2018
Advicenne (Paris:ADVIC), a specialist pharmaceutical company focused on the development of pediatric-friendly therapeutics for the treatment of orphan renal and neurological diseases, announces preliminary results of the Phase III Extension Study.
-
Advicenne Appoints Linda Law, MD as U.S. VP, Clinical Development
1/24/2018
Dr. Law will oversee Advicenne's clinical development and medical affairs efforts in North America which are focused on the Company's most advanced program, ADV7103.
-
Advicenne Announces Positive 6-Month Extension Study Data from Pivotal Phase III Study of ADV7103 in Adults and Children Suffering From Distal Renal Tubular Acidosis (dRTA)
11/6/2017
The extension study followed the pivotal phase III trial, which showed ADV7103's ability to restore the main biological defects observed with the disease, meeting primary and secondary endpoints.